I’ve a piece up at The New Yorker on 23andMe’s clash with the FDA: Here’s the opening: The United States Food and Drug Administration is not known for its prose. So the warning letter that it sent to 23andMe, the direct-to-consumer genetic-testing company, on November 22nd, was a surprise in more ways than one. “It reads like […]
Continue reading →Held: A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated. The Supreme Court of the United States decides the Myriad gene-patenting case. Here’s the decision. Lots of coverage to come.
Continue reading →The ever-excellent Neurocritic has an interesting post looking at “lesion studies” of depression. As he notes, he was hoping for real lesions, from people who’d had psychosurgery years ago, but had to settle for a simulation study that used MRIs from a large sample of control participants.
Continue reading →